AAV-PCSK9 Atherosclerosis Model: Benefits, Workflow & Applications | OBiO

Atherosclerosis is a chronic inflammatory disease of the arteries and is primarily driven by lipid accumulation and inflammation. The accumulation of low-density lipoprotein (LDL) and remnant lipoprotein particles, together with active inflammatory responses in the arterial wall, contributes to atherosclerotic plaque formation and can ultimately lead to myocardial infarction, stroke, and peripheral artery disease. Major risk factors for atherosclerosis include hypercholesterolemia, hypertension, diabetes, and obesity.

Animal models of atherosclerosis are essential for investigating the molecular mechanisms underlying disease development and progression, as well as for evaluating potential preventive and therapeutic strategies for cardiometabolic diseases.

The most commonly used traditional mouse models of atherosclerosis include ApoE^-/- mice and LDLR^-/- mice. However, these genetically engineered models have several limitations. They are largely restricted to specific mouse genetic backgrounds, provide limited flexibility for studying interactions with other genetic modifications, and may require time-consuming breeding to generate compound mutant models.

Around 2014, researchers introduced a non-germline-engineering approach for inducing atherosclerosis: AAV-PCSK9 administration combined with a high-fat diet. This approach has since been widely adopted as a flexible model for experimental atherosclerosis research.

How Does the AAV-PCSK9 Model Work?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted proteinase primarily expressed in the liver. PCSK9 binds to low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes and promotes their lysosomal degradation. This reduces hepatic clearance of circulating LDL and consequently increases plasma low-density lipoprotein cholesterol (LDL-C) levels.

Based on this mechanism, researchers use AAV vectors to deliver gain-of-function PCSK9 variants, such as human PCSK9-D374Y or mouse PCSK9-D377Y, to the liver. This enables sustained hepatic production and secretion of highly active PCSK9 protein. Elevated PCSK9 activity accelerates LDLR degradation and impairs the hepatic LDL-C clearance pathway. When combined with a high-fat diet, this results in a rapid increase in circulating LDL-C levels and can induce hypercholesterolemia and atherosclerotic lesions, providing a practical model for studyingcardiometabolic disease.

Figure 1. PCSK9 binding to the LDL receptor on the hepatocyte surface

(ManalAlkindi et al., Canadian Journal of Cardiology, 2016)

Figure 2. Schematic representation of the AAV-PCSK9 plasmid

(MartinMæng Bjørklund et al., Circulation Research, 2014)

Key Advantages of the AAV-PCSK9 Atherosclerosis Model

🔷 No germline genetic modification required

AAV-PCSK9 can induce atherosclerotic phenotypes in mice with different genetic backgrounds, including mice carrying specific genetic modifications or immune-deficient backgrounds. This provides greater flexibility when combining atherosclerosis modeling with other disease models or genetic manipulations.

🔷 Applicable to multiple animal models

AAV-PCSK9-based modeling can be explored in different experimental species. In addition to mice, previous studies have demonstrated that AAV-PCSK9 can also be used to establish atherosclerosis models in hamsters.

🔷 Lipid profiles more closely reflect human atherosclerosis

The AAV-PCSK9 model primarily increases LDL-C, a key driver of human atherosclerosis. In contrast, ApoE-/- mice predominantly exhibit elevated very-low-density lipoprotein (VLDL)-rich lipoproteins. Therefore, the AAV-PCSK9 model can more closely recapitulate the LDL-C-driven component of human atherosclerosis, making it particularly useful for studying LDL-targeted therapies such as statins and PCSK9 inhibitors.

🔷 Flexible control of disease severity

Disease progression can be modulated by adjusting the AAV dose and dietary regimen, allowing researchers to model different levels of atherosclerotic burden.

🔷 Direct relevance to the PCSK9-LDLR pathway

PCSK9 is an established target of cardiovascular research. The AAV-PCSK9 model provides a useful system for investigating the PCSK9-LDLR pathway and evaluating PCSK9-targeted therapeutic approaches, including PCSK9 inhibitors.

🔷 Suitable for candidate gene and drug target screening

The model can be used in studies designed to identify candidate genes, molecular pathways, or therapeutic targets that influence atherosclerosis development.

AAV-PCSK9 Atherosclerosis Model: Typical Workflow

Common AAV Vector

Experimental Animals

8-week-old C57BL/6J mice, C57BL/6NTac mice, or other suitable mouse strains

Tail-Vein Administration

2–5 × 10¹¹ vg/mouse

High-Fat Diet

Following AAV administration, mice are maintained on a high-fat diet to promote hypercholesterolemia and atherosclerotic lesion development.

Sample Collection and Assessment

• 6–12 weeks: Significant elevation in circulating lipid levels
• 12–16 weeks: Development of aortic atherosclerotic lesions
• Around 20 weeks: Aortic calcification may become detectable

The time points above are provided for reference only. Actual disease progression may vary depending on the animal model, AAV dose, dietary regimen, and experimental conditions.

Customer Case Study

In 2024, a research team published a study in Advanced Science investigating the role of CD34+ cells in abdominal aortic aneurysm (AAA).

To increase the incidence of aneurysm formation, the researchers needed to induce hypercholesterolemia in genetically modified mice. They used an AAV-PCSK9 vector constructed by OBiO in combination with a high-fat diet to establish the hypercholesterolemic model.

The study demonstrated that AAV-PCSK9-mediated induction of hypercholesterolemia increased the incidence of aortic aneurysm, providing an experimental model for investigating the mechanisms underlying aneurysm development.

Figure 3. AAV-PCSK9-induced hypercholesterolemia increases the incidence of aortic aneurysm

(Hong Wu et al., Advanced Science, 2025)

OBiO AAV-PCSK9 Ready-to-Use Vector

GMP-Based Manufacturing · Enhanced Quality

Manufactured using a GMP-based process with high-standard purification and ddPCR-based viral genome titration.

Batch-to-Batch Consistency · Reliable Supply

Large-scale production within the same batch, with a yield of more than 1 E14 vg per batch, supporting long-term experimental needs.

Ready to Ship · Accelerate Your Research

No lengthy custom production cycle. Ready-to-use AAV-PCSK9 vectors can help researchers move more quickly from model establishment to cardiovascular and cardiometabolic disease studies.

References

1. Alkindi M, Siminovitch KA, Gupta M, Genest J. Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. Can J Cardiol. 2016;32(12):1552-1560.
2. Bjørklund MM, Hollensen AK, Hagensen MK, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014;114(11):1684-1689.
3. Wu H, Yang X, Chen T, et al. Aneurysm Is Restricted by CD34+ Cell-Formed Fibrous Collars Through the PDGFRβ-PI3K Axis. Adv Sci (Weinh). 2025;12(7):e2408996.